Natera Inc

2026-10-09 20:07; UTC

Natera Inc.'s multi-cancer early detection assay received Breakthrough Device designation from the FDA, aimed at improving early cancer diagnosis and treatment options.

2026-10-08 20:07; UTC

Baird analyst Catherine Ramsey Schulte raised Natera Inc's price target to $458.00 from $376.00 while maintaining an Outperform rating.

2026-10-07 20:00; UTC

Natera Inc. shares fell despite the enrollment of patients in a study for advanced melanoma and Barclays raising its price target to $475 from $340.

2026-10-06 20:00; UTC

Natera Inc shares fell amid broader biotechnology sector weakness, despite positive data on its Signatera product and Citigroup raising its price target to $480.

2026-10-05 23:05; UTC

Citi raised its price target on Natera Inc to $480 from $365, maintaining a Buy rating amid growth in its Signatera product and health segments.

2026-10-02 20:07; UTC

Natera Inc shares are higher amid a broadly advancing market, reflecting positive momentum as labor statistics influence expectations for future interest rates.

2026-10-01 20:07; UTC

Natera Inc shares are declining, reversing earlier gains despite remaining above the 20-day moving average and near the upper end of the one-month range.

2026-09-30 23:00; UTC

Natera Inc declined in after-market trading, settling below Wednesday's close after retreating from an early high, despite remaining higher over the past month.

2026-09-29 19:15; UTC

Natera Inc shares are modestly higher as social media buzz highlights positive cash flows and a potential cancer screening test amid market volatility.

2026-09-28 20:07; UTC

Natera's shares fell amid a broader market decline, despite RBC Capital raising its price target to $460 and maintaining an Outperform rating.

2026-09-25 19:46; UTC

RBC Capital raised its price target on Natera Inc to $460, maintaining an Outperform rating, as shares trade modestly higher amid strong market position.

2026-09-24 23:01; UTC

Natera Inc is trading modestly lower in after-market hours, having retraced from an early gain and reflecting a cumulative decline since Thursday's close.

2026-09-22 20:02; UTC

Natera Inc's Signatera test received regulatory approval in Japan as a companion diagnostic for muscle-invasive bladder cancer, driving the stock sharply higher.

2026-09-21 22:11; UTC

Natera Inc is trading modestly higher in after-market hours, remaining well above its 20-day moving average following a peak earlier in the session.

2026-09-18 22:31; UTC

Natera Inc declined in after-market trading, moving lower since Friday's close, despite previously trading above its 20-day moving average.

2026-09-17 23:06; UTC

Natera Inc's shares traded flat in after-market hours, remaining 10.18% above the 20-day moving average amid positive economic indicators.

2026-09-16 19:07; UTC

Natera Inc shares fell modestly lower, reaching a notable low today, though remaining above their 20-day moving average.

2026-09-15 23:01; UTC

Natera Inc shares are higher in after-market hours following Tuesday's close, continuing a trend of four consecutive sessions that also closed higher.

2026-09-14 19:26; UTC

Natera Inc is gaining momentum as it breaks above September's value area. UBS raised its price target while maintaining a "buy" rating.

2026-09-11 22:51; UTC

Natera Inc shares are lower in after-market hours, with no specific news identified to explain the movement. Broader market sentiment may be influencing trading.

2026-09-09 20:07; UTC

UBS has raised its price target on Natera Inc. to $435, maintaining a Buy rating and contributing to a rise in shares during Wednesday's session.

2026-09-08 23:06; UTC

Natera Inc. shares are higher in after-market trading, maintaining upward momentum since Tuesday's close despite an earlier pullback. The stock is above its 20-day moving average.

2026-09-03 19:36; UTC

Baird raised Natera's price target to $376 from $348, maintaining an Outperform rating. Shares are higher since Wednesday's close amid easing interest rate concerns.

2026-09-02 23:26; UTC

Natera Inc. shares are higher in after-market trading, continuing a strong performance over the past month, well above the 20-day moving average.

2026-09-01 19:36; UTC

Natera's Signatera test shows 100% predictive value for lymphoma treatment responses, boosting shares higher during Tuesday's session.

2026-08-31 23:01; UTC

Natera Inc shares are higher in after-market trading, stabilizing near earlier highs amid broader economic concerns over potential interest rate hikes.

2026-08-28 20:02; UTC

Natera Inc partners with Susan G. Komen to enhance breast cancer education. Shares are lower amid high trading volume and broader market pressures.

2026-08-27 20:07; UTC

Natera partners with Angiex to use Signatera in a Phase I trial for AGX101, aimed at enhancing cancer treatment response evaluation. Shares are roughly flat.

2026-08-26 19:26; UTC

Natera Inc's shares are higher today, reflecting a general market uptrend. The stock remains above its 20-day moving average and near a one-month high.

2026-08-24 19:46; UTC

Natera Inc shares are lower today, pulling back from earlier session highs. Rising oil prices and geopolitical tensions impact overall market sentiment.